MedTrace Logo

Correction of Anaemia and Progression of Renal Failure on Transplanted Patients

NCT00396435 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-09-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate, on renal transplanted patients with CGD, the effect of two levels of haemoglobin on quality of life at 6 months and the speed of progression of renal function degradation at 24 months.

This study will recruit 140 patients in 21 centers in France.

Conditions

Interventions

DRUG

Neorecormon

Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Principal Investigators

  • Gabriel Choukroun, MD, PhD · CHU Amiens

  • Franck Martinez, MD, PhD · Hôpital Necker- Enfants Malades - PARIS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-04-30
Completion
2010-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00396435 on ClinicalTrials.gov